Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
-
+
EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Presentations: 108
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP08.01-090 - Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront.
Author(s): Javier Torres Jiménez- Abstract
Loading... -
+
EP08.01-091 - Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone +/- Chemotherapy Upfront
Author(s): Teresa Gorria- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Presentations: 171
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP08.02-041 - NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study
Author(s): Alexander Drilon- Abstract
Loading... -
+
EP08.02-016 - Frontline and Post-Osimertinib Therapy for EGFR-mutant Advanced NSCLC: Treatment Patterns, Outcomes, Healthcare Use and Costs
Author(s): Nicolas Girard- Abstract
Loading... -
+
EP08.02-173 - Treatment Patterns and Outcomes Among Patients With EGFR-mutant Advanced NSCLC in the Frontline and Post-Osimertinib Settings
Author(s): Joshua Sabari- Abstract
Loading...
-
+
ES07 - Impact of Tumor Plasticity and Molecular/Immune Adaptations in Treatment Sensitivity and Resistance
- Type: Education Session
- Track: Tumor Biology and Biomarkers
- Presentations: 9
- Moderators:Benjamin Besse
- Coordinates: 8/07/2022, 12:00 - 13:00, Strauss 1/2
-
+
ES07.01 - Session Introduction
12:00 - 12:01 | Author(s): Benjamin Besse
- Abstract
Loading... -
+
ES07.02 - Session Introduction
12:01 - 12:02 | Author(s): Yuko Minami
- Abstract
Loading... -
+
ES07.03 - NSCLC Persister Cells and Their Role in Treatment Resistance and Disease Progression
12:02 - 12:14 | Author(s): Trever Bivona
- Abstract
Loading... -
+
ES07.04 - Biological Role and Actionability of Molecular/Immune Alterations after Acquired Resistance to Single-Agent and Combination Therapies (Focus on EMT, Includes SCLC)
12:14 - 12:26 | Author(s): Sandra Ortiz-Cuaran
- Abstract
Loading... -
+
ES07.05 - Tumor Cell Plasticity and Histological/Molecular Changes: Focus On Transition from NSCLC to SCLC
12:26 - 12:38 | Author(s): Triparna Sen
- Abstract
Loading... -
+
ES07.06 - Biological Advances in SCLC: Molecular Subtypes, Anti-tumor Immune Responses and Impact on Therapeutics
12:38 - 12:50 | Author(s): Helmut Popper
- Abstract
Loading... -
+
ES07.07 - Live Q&A
12:50 - 13:00
- Abstract
Loading... -
+
Session Moderator
12:50 - 13:00 | Author(s): Benjamin Besse
- Abstract
Loading... -
+
Session Moderator
12:50 - 13:00 | Author(s): Yuko Minami
- Abstract
Loading...
-
+
P1.16 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Type: Regular Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Presentations: 4
- Coordinates: 8/07/2022, 17:00 - 19:00, Exhibit Hall - Hall B
-
+
P1.16-02 - Clinical Utility of ctDNA in Advanced NSCLC at Diagnosis or Where Insufficient Tissue Was Available, Based on the ESMO ESCAT Scale
Author(s): Laura Mezquita- Abstract
Loading...
-
+
PL03 - Plenary 3: Presidential Symposium - Top Rated Abstracts (Live Streamed Session)
- Type: Plenary
- Track: N/A
- Presentations: 17
- Moderators:Heather Wakelee
- Coordinates: 8/08/2022, 08:30 - 10:20, Hall C1
-
+
PL03.10 - Discussant
Author(s): Benjamin Besse- Abstract
Loading...
-
+
OA07 - Is There Still a Role for Chemotherapy Alone in the Management of NSCLC?
- Type: Oral
- Track: Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy
- Presentations: 10
- Moderators:Lubos Petruzelka
- Coordinates: 8/08/2022, 11:00 - 12:00, Hall C7
-
+
OA07.06 - Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC)
11:32 - 11:42 | Author(s): Edouard Auclin
- Abstract
Loading...
-
+
MA07 - Overcoming Resistance to EGFR Inhibitors
- Type: Mini Oral
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Presentations: 13
- Moderators:Dana Lucia Stanculeanu
- Coordinates: 8/08/2022, 12:15 - 13:15, Hall C7
-
+
MA07.07 - Clinical/Molecular Profile of Patients with Non-small Cell Lung Cancer (NSCLC) with Incidental Pathogenic Germline Variants Detected in cfDNA
12:42 - 12:47 | Author(s): Laura Mezquita
- Abstract
Loading...
-
+
MA10 - Updates in Thymoma
- Type: Mini Oral
- Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies
- Presentations: 13
- Moderators:Noboru Yamamoto
- Coordinates: 8/08/2022, 14:45 - 15:45, Hall C8
-
+
MA10.08 - Activated Pathways of Myastenia Gravis in Thymic Epithelial (TETs)
15:17 - 15:22 | Author(s): Jose Carlos Benítez
- Abstract
Loading...
-
+
OA13 - Evolving Epidemiology of Lung Cancer Beyond Tobacco
- Type: Oral
- Track: Epidemiology
- Presentations: 10
- Moderators:Matthew T Warkentin
- Coordinates: 8/09/2022, 10:45 - 11:45, Hall C8
-
+
OA13.04 - Prevalence of Molecular Alterations in NSCLC and Estimated Indoor Radon in Europe: RADON EUROPE Study
10:57 - 11:07 | Author(s): Miguel Garcia Pardo
- Abstract
Loading...
-
+
OA15 - Patient Selection in Advanced NSCLC Immunotherapy
- Type: Oral
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Presentations: 10
- Moderators:Pilar Garrido
- Coordinates: 8/09/2022, 14:30 - 15:30, Hall C7
-
+
OA15.05 - HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed Phase 2 Study in NSCLC Patients Who Progressed on Anti-PD-(L)1 Therapy
14:52 - 15:02 | Author(s): Benjamin Besse
- Abstract
Loading...